Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Long-term Investments
Investments the company intends to hold for more than a year.
Canopy Growth CorporationNASDAQ: CGC
Long-term Investments · Q4 FY2025 · quarter ended Mar 2026
Long-term investments rises 25.0% from a year ago
Long-term investments stood at CA$44.11M at the end of Q4 FY2025, up 25.0% from a year earlier and down 32.0% from the prior quarter. Over 3 fiscal years it compounded at -35.8% a year.
Context
- Long-term investments amounted to 3.9% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +25.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
CAD · from the balance sheet
- Latest · FY2025
- 150.63M CAD
- Year-over-year change
- +326.8%
- 4-year CAGR
- -18.5%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 150.63M | +326.8% |
| FY2024 | 2025-03-31 | 35.29M | -74.1% |
| FY2023 | 2024-03-31 | 136.22M | -76.0% |
| FY2022 | 2023-03-31 | 568.29M | +66.3% |
| FY2021 | 2022-03-31 | 341.73M | — |
Long-term Investments vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +25.0% is the 2nd highest of 5, against a peer median of -30.1%.
- Long-term investments amounts to 3.9% of total assets for CGC, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.37M USD | +0.2% | +70.4% | 43.0% | |
| Mar 2026 | CA$44.11M CAD | +25.0% | -35.8% | 3.9% | |
| Mar 2026 | $19M USD | -60.4% | -45.1% | 5.4% | |
| Mar 2026 | CA$15.82M CAD | +202.7% | +4.8% | 2.6% | |
| Mar 2026 | $552K USD | — | — | 0.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $100K USD | -99.3% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CGC) | — | -30.1% | +4.8% | 0.0% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 776.01M | 667.69M | 170.3M | 113.81M | 508.58M |
| Short-term Investments | 595.65M | 105.53M | 33.16M | 17.66M | 5.06M |
| Net Receivables | 86.58M | 68.46M | 51.85M | 52.78M | 36.29M |
| Inventory | 204.54M | 83.23M | 77.29M | 96.37M | 154.12M |
| Other Current Assets | 31.28M | 138.17M | 29.59M | 8.44M | 39.39M |
| Total Current Assets | 1.73B | 1.08B | 371.18M | 294.57M | 738.38M |
| Property, Plant & Equipment (Net) | 942.78M | 471.27M | 320.1M | 293.52M | 441.37M |
| Goodwill | 1.87B | 85.56M | 43.24M | 46.04M | 77.66M |
| Intangible Assets | 252.7M | 160.75M | 104.05M | 87.2M | 128.87M |
| Long-term Investments | 341.73M | 568.29M | 136.22M | 35.29M | 150.63M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 473.94M | 76.57M | 325.53M | 161.07M | 23.24M |
| Total Non-current Assets | 3.88B | 1.36B | 929.15M | 623.13M | 821.77M |
| Total Assets | 5.61B | 2.44B | 1.3B | 917.7M | 1.56B |
| Account Payables | 64.27M | 31.84M | 28.67M | 26.1M | 34.82M |
| Short-term Debt | 9.3M | 556.89M | 103.94M | 4.26M | 22.64M |
| Tax Payables | 7.14M | 5.73M | 10.52M | 13.07M | 0 |
| Deferred Revenue | 0 | 0 | 5.85M | 0 | 0 |
| Other Current Liabilities | 76.71M | 175M | 53.77M | 31.73M | 134.77M |
| Total Current Liabilities | 213.19M | 803.84M | 234.72M | 94.4M | 220.96M |
| Long-term Debt | 1.49B | 749.99M | 493.29M | 299.81M | 302.79M |
| Deferred Tax Liabilities | 15.99M | 357K | 0 | 0 | 11.43M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 162.84M | 47.12M | 16.22M | 8.49M | 6.35M |
| Total Non-current Liabilities | 1.77B | 875.83M | 565.11M | 336.08M | 366.35M |
| Total Liabilities | 1.98B | 1.68B | 799.82M | 430.49M | 587.31M |
| Common Stock | 7.48B | 7.94B | 8.24B | 8.8B | 9.23B |
| Retained Earnings | (6.38B) | (9.67B) | (10.33B) | (10.93B) | (11.14B) |
| Accumulated OCI | (42.28M) | (13.86M) | (16.05M) | 535K | 10.53M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 36.84M | 1.59M | 139K | 0 | 0 |
| Total Equity | 3.62B | 760.02M | 500.51M | 487.21M | 972.84M |
| Total Debt | 1.64B | 1.41B | 668M | 348.4M | 325.44M |
| Net Debt | 864.15M | 745.98M | 497.7M | 234.59M | (183.14M) |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.